Liraglutide and Dapagliflozin combination synergistically reshapes gut microbiota and ameliorates Type-2 Diabetes in mice
Background
Type-2 diabetes mellitus (T2DM) remains a significant global health challenge, characterized by persistent hyperglycemia stemming from insulin resistance and progressive β-cell dysfunction. While liraglutide (LIRA), a GLP-1 receptor agonist, and dapagliflozin (DAPA), an SGLT2 inhibitor, are established therapies with complementary mechanisms, the full extent of their synergistic potential, especially through modulation of the gut microbiota and host metabolism, is not completely understood. This study aimed to elucidate the gut microbiota-metabolite axis underlying the therapeutic effects of this combination in T2DM.
Study Design
Researchers induced a T2DM mouse model using a high-fat diet and streptozotocin. Mice were then treated for 4 weeks with LIRA, DAPA, or their combination (COM). The study assessed several key parameters, including glycemic control, insulin sensitivity, and pancreatic islet morphology. Additionally, serum biochemistry was analyzed, alongside comprehensive gut microbiota profiling via shotgun metagenomic sequencing and plasma metabolome analysis using nontargeted metabolomics. An integrated multiomics approach was employed to understand the complex microbiota-metabolite interactions.
Results
Combination treatment with Liraglutide and Dapagliflozin demonstrated superior efficacy compared to either monotherapy, leading to significantly greater improvements across multiple metabolic parameters. This included enhanced body weight management, improved glucose tolerance, and increased insulin sensitivity. Lipid profiles and liver function also showed marked improvements. Histological analysis revealed that the COM therapy was most effective in restoring pancreatic islet architecture, increasing β-cell mass, and normalizing the α/β-cell ratio. Metagenomic analysis confirmed that COM induced a unique and restorative remodeling of the gut microbiota, distinctly different from monotherapies. This beneficial shift was characterized by the suppression of pathobionts, such as Klebsiella and Enterorhabdus, and a notable enrichment of beneficial taxa, including Akkermansia, Lactobacillus, and Faecalibaculum.
Key Findings
- Liraglutide and dapagliflozin combination therapy significantly improved body weight, glucose tolerance, and insulin sensitivity in T2DM mice.
- Combination treatment most effectively restored pancreatic islet architecture, increased β-cell mass, and normalized the α/β-cell ratio.
- The combination uniquely remodeled gut microbiota, suppressing pathobionts like
KlebsiellaandEnterorhabdus. - Beneficial gut bacteria, including
Akkermansia,Lactobacillus, andFaecalibaculum, were enriched by the combination therapy. - Combination therapy extensively normalized the diabetic plasma metabolome, particularly impacting
tryptophan metabolism.
Why It Matters
This research highlights the profound synergistic potential of combining Liraglutide and Dapagliflozin for T2DM management, extending beyond their individual effects to include beneficial gut microbiota remodeling. For individuals managing T2DM, this suggests that combination therapy could offer a more comprehensive approach to disease control, potentially leading to better glycemic outcomes and improved pancreatic health. The findings underscore the importance of the gut microbiota as a therapeutic target in diabetes and indicate that optimized T2DM protocols could leverage this dual-mechanism strategy to address both metabolic dysfunction and gut dysbiosis. This preclinical evidence supports further investigation into clinical applications, potentially paving the way for enhanced treatment regimens.
liraglutide
dapagliflozin
t2dm
gut-microbiota
metabolomics
preclinical-animal